Beyond Cut Points: Accelerometer Metrics that Capture the Physical Activity Profile

Purpose Commonly used physical activity metrics tell us little about the intensity distribution across the activity profile. The purpose of this paper is to introduce a metric, the intensity gradient, which can be used in combination with average acceleration (overall activity level) to fully describe the activity profile. Methods A total of 1669 adolescent girls (sample 1) and 295 adults with type 2 diabetes (sample 2) wore a GENEActiv accelerometer on their nondominant wrist for up to 7 d. Body mass index and percent body fat were assessed in both samples and physical function (grip strength, Short Physical Performance Battery, and sit-to-stand repetitions) in sample 2. Physical activity metrics were as follows: average acceleration (AccelAV); the intensity gradient (IntensityGRAD from the log–log regression line: 25-mg intensity bins [x]/time accumulated in each bin [y]); total moderate-to-vigorous physical activity (MVPA); and bouted MVPA (sample 2 only). Results Correlations between AccelAV and IntensityGRAD (r = 0.39–0.51) were similar to correlations between AccelAV and bouted MVPA (r = 0.48) and substantially lower than between AccelAV and total MVPA (r ≥ 0.93). IntensityGRAD was negatively associated with body fatness in sample 1 (P
Source: Medicine and Science in Sports and Exercise - Category: Sports Medicine Tags: SPECIAL COMMUNICATIONS: Methodological Advances Source Type: research

Related Links:

AbstractPurposeSleep problems are very common in people with diabetes. The aim of this study was to assess the association of the combination of self-reported sleep duration and sleep quality on quality of life (QOL) in Chinese patients with type 2 diabetes mellitus (T2DM).MethodsWe analyzed the community-based cross-sectional data of 798 patients with T2DM in Xiamen, China, in 2016. Sleep duration was measured as self-reported average sleep time during the previous month. Sleep quality was evaluated as self-rated reports. QOL was assessed by the Diabetes-specific Quality of Life (DSQL), with scores  
Source: Quality of Life Research - Category: Health Management Source Type: research
Source: BMJ Comments - Category: General Medicine Source Type: forums
Authors: Gómez-Sámano MÁ, Almeda-Valdes P, Cuevas-Ramos D, Navarro-Flores MF, Espinosa-Salazar HD, Martínez-Saavedra M, León-Domínguez JA, Enríquez-Estrada VM, López-González AL, Sarmiento-Moreno AL, Rivera-González LA, Juárez-León ÓA, Pérez-González B, Ávila-Palacios Y, Sigala-Pedroza L, Huerta-Ávila E, Vargas-Álvarez MA, Sánchez-Jaimes C, Cárdenas-Vera M, Mehta R, López-Flores A La Torre MA, Manjarrez-Martínez I, Brito-Córdova GX, Zuarth-Vázquez JM, Vega-B...
Source: International Journal of Nephrology - Category: Urology & Nephrology Tags: Int J Nephrol Source Type: research
DIABETES type 2 risk could be lowered by making some diet or lifestyle changes. Adding these five diabetes “superfoods” could help to lower the risk of high blood sugar symptoms. Are you at risk of developing diabetes signs?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
ConclusionREHIT may offer a genuinely time-efficient exercise option for improving 24-h glycaemia in men with type 2 diabetes and warrants further study.
Source: European Journal of Applied Physiology - Category: Physiology Source Type: research
EMPA-HEART Cardiolink-6 trial results suggest that the SGLT2 inhibitor is linked to reduced left ventricular mass, a surrogate for reduced heart failure, in patients with CVD and type 2 diabetes.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news
TUESDAY, Nov. 13, 2018 -- Treatment with dapagliflozin is noninferior to placebo for major adverse cardiovascular events (MACE) among patients with type 2 diabetes with or at risk for atherosclerotic cardiovascular disease, according to a study...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
BRIDGEWATER, N.J., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one,wearable insulin delivery option for patients with diabetes, announced today a poster titled“Relationship between Baseline BMI and Clinical Outcomes with V-Go® Wearable Insulin Delivery Device in Patients with Type 2 Diabetes Previously Prescribed Basal-Bolus Regimens”...This story is related to the following:Medical Devices
Source: Industrial Newsroom - Health, Medical and Dental Supplies - Category: Medical Devices Source Type: news
TYPE 2 diabetes can be controlled by eating the right kind of diet and cutting down on foods that are high in sugar, fat and salt. If you have diabetes but love cheese, try replacing your regular choice with this type to keep the condition under control.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Rodrigo S. Delevatti, Ana Carolina Kanitz, Cristine L. Alberton, Elisa Corr êa Marson, Patricia Dias Pantoja, Carolina DertzbocherFeil Pinho, Salime Chedid Lisboa, Luiz Fernando M. Kruel
Source: Frontiers in Physiology - Category: Physiology Source Type: research
More News: Diabetes | Diabetes Type 2 | Endocrinology | Girls | Science | Sports Medicine